[ET Net News Agency, 27 March 2020] WuXi Biologics (Cayman) Inc. (02269) said its
profit attributable to equity shareholders of the company was RMB1,013.8 million for the
year ended 31 December 2019, a year-on-year increase of 60.8%. The basic earnings per
share were RMB0.82. No dividend will be distributed.
The revenue was RMB3,983.7 million, a year-on-year increase of 57.2%. (RC)